Advanz Pharma
In July 2021 the Competition and Markets Authority found that the company "exploited a loophole enabling it to reap much higher profits". They and HgCapital and Cinven, 2 former owners of the  business were fined  a total of £84 million. It had raised the price of liothyronine tablets from £6 a pack to £248 in 2017. They appealed but in 2023 the Competition Appeal Tribunal turned down their appeal.